Syngene

Ref: Syn/CS/SE/PR/April/2019-20/03

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099,
India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937
www.syngeneintl.com

April 5, 2019

To,	To,
The Manager Listing	The Manager Listing
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Corporate Communication Department
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Subject: Press Release-Syngene International Limited

In pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled **"Syngene International and BIRAC set up Centre for Advanced Protein Studies (CAPS)".**

The above mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Mayank Verma
Company Secretary and Compliance Officer

Syngene International Limited ★ Bangalore ★



PRESS RELEASE

Syngene International and BIRAC set up Centre for Advanced Protein Studies (CAPS)

Collaboration part of National Biopharma Mission

5th April, 2019, Bengaluru

Syngene International Ltd., a leading global contract research organization, announced the opening of its Centre for Advanced Protein Studies (CAPS) by the Secretary, Department of Biotechnology, Government of India. The Centre has been set up in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC) at Syngene's campus in Bengaluru and will host a state-of-the-art GLP accredited analytical laboratory.

Regulatory approval of complex biological molecules involves extensive and advanced analytics including assessment of physiochemical characteristics, efficacy, immunogenicity (antidrug antibody), contamination, strength and more. All these tests need to be performed in a GLP compliant analytical facility. Availability of appropriate certified facilities at affordable costs is a challenge that the start-ups, SMEs/MMEs and the academia in India, have to often face.

CAPS will help address this challenge and will be a big boost in advancing biopharma research and product development in India. Spread across an area of 2000 sq. ft, the Centre will run under the 'Innovate in India' program of the National Biopharma Mission, Department of Biotechnology, announced by the Government of India.

Speaking on the occasion, Kiran Mazumdar Shaw, Managing Director, Syngene International Ltd. said, *"I am extremely excited to see this partnership between Syngene and BIRAC. In the last few years, India's biotechnology sector has seen tremendous action. India has immense scientific and entrepreneurial talent available in the country which gives it strong potential to emerge as the R&D hub for the global biotechnology industry. The CAPS facility will provide the right ecosystem for this talent to pursue their research objectives."*



PRESS RELEASE

Jonathan Hunt, Chief Executive Officer, Syngene International Ltd., said, "*It is indeed an honour for Syngene to collaborate with BIRAC in setting up the CAPS facility. As India's largest scientific services provider, this collaboration will help Syngene play an active role in the development of India's biotechnology industry as well as nurture the innovative spirit within the industry.*"

Apart from providing the necessary infrastructure support at affordable cost, CAPS will also focus on advancing technical skill development to global standards, by conducting various trainings and workshops involving eminent subject experts.

National Biopharma Mission is an industry-academia collaborative mission of the Department of Biotechnology (DBT) and World Bank for accelerating early development of biopharmaceuticals and is being implemented by BIRAC.

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation focused global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene's clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 3500-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com

For further information, please reach out to:

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com